Across
- 2. Lung function test central to COPD and ACO diagnosis
- 5. Observable clinical cluster; three distinct ACO variants found
- 9. AI capability — forecasting exacerbations using real-world data
- 10. Inhaled corticosteroids, used cautiously in overlap phenotypes
- 11. Monoclonal antibody class for eosinophilic ACO
- 12. CT finding reduced in ACO vs pure COPD
- 13. Acute worsening event now predictable by AI models
- 14. Global Initiative for Asthma — GOLD's partner in jointly redefining ACO framework
Down
- 1. Measurable indicator guiding ACO diagnosis and treatment
- 3. Co-existence of asthma and COPD features
- 4. Global Initiative for Chronic Obstructive Lung Disease — co-author of 2025–26 joint statement
- 6. Elevated blood count driving biologic selection in T2 ACO
- 7. Medicine paradigm using biomarkers to tailor therapy
- 8. Disease subtype defined by biological mechanism
